{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:00:41Z","timestamp":1780470041031,"version":"3.54.1"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Drug Deliv."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Ursolic acid (UA), the antimalarial triterpenic mixture 8TTE (containing C-27 feruloyl and coumaroyl esters of ursane and oleane skeletons), and the semi-synthetic antitrypanosomal derivative ursolic acid O-phenyl propionate (UAOPP) exhibit high lipophilicity, which may limit their oral bioavailability. This study aimed to develop lipid nanocapsules (LNCs) to improve the solubility, intestinal permeability, and antiparasitic activity of these triterpenic compounds for potential oral delivery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      LNCs formulations containing UA, 8TTE, and UAOPP were prepared and evaluated. A sensitive UPLC\\x{2013}MS method was developed and validated for selected triterpenes quantification during transport studies across Caco-2 cell monolayers [limit of detection (LOD): 2 nM; limit of quantification (LOQ): 25 nM]. Cytotoxicity and permeability studies were conducted on Caco-2 cells to assess formulation safety and intestinal transport.\n                      <jats:italic>In vitro<\/jats:italic>\n                      antiparasitic activity of free and formulated compounds was evaluated against\n                      <jats:italic>Plasmodium falciparum<\/jats:italic>\n                      and\n                      <jats:italic>Trypanosoma brucei brucei<\/jats:italic>\n                      (Tbb).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results and discussion<\/jats:title>\n                    <jats:p>\n                      The formulations were non-toxic to Caco-2 cells at concentrations up to 2 mg\/mL. Permeability studies demonstrated enhanced transport for the formulated triterpenic esters, with permeability increases of up to 2.68-fold, shifting their classification from poorly absorbed to moderately absorbed compounds in humans [apparent permeability coefficient (Papp) &amp;gt; 1 \u00d7 10\n                      <jats:sup>\u20136<\/jats:sup>\n                      cm\/s]. Free UA showed the highest Papp value (4.95 \u00d7 10\n                      <jats:sup>\u20136<\/jats:sup>\n                      cm\/s \u00b1 1.29 \u00d7 10\n                      <jats:sup>\u20137<\/jats:sup>\n                      ), but caused epithelial integrity disruption after 2 h of incubation and during the following 48 h, whereas formulated UA induced minimal integrity loss at the same concentration. In antiparasitic assays, blank LNCs exhibited maximum non-toxic concentrations of 165 \u03bcg\/mL against\n                      <jats:italic>P. falciparum<\/jats:italic>\n                      and 65 \u03bcg\/mL against Tbb. At these maximum concentrations, formulated UA and 8TTE showed enhanced antiplasmodial activity; however, blank LNCs produced comparable effects. In contrast, UAOPP-loaded LNCs showed significantly improved antitrypanosomal activity by approximately 20% at 2.15 \u03bcM (cell viability: 38.20% \u00b1 5.41) compared with free UAOPP (20.38% \u00b1 8.80). These findings suggest that LNCs represent promising oral delivery systems for lipophilic triterpenes. Further in vivo pharmacokinetic and efficacy studies are needed to confirm their therapeutic potential.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fddev.2026.1846904","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:01:45Z","timestamp":1780466505000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Antiparasitic triterpenic ester and ursolic acid lipid nanocapsule design, cytotoxicity, and permeability evaluation for oral delivery"],"prefix":"10.3389","volume":"6","author":[{"given":"Laura","family":"Schioppa","sequence":"first","affiliation":[{"name":"Pharmacognosy Research Group, Louvain Drug Research Institute (LDRI), Universit\u00e9 Catholique de Louvain (UCLouvain)","place":["Brussels, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia Bohns","family":"Michalowski","sequence":"additional","affiliation":[{"name":"Department of Advanced Drug Delivery and Biomaterials, Louvain Drug Research Institute (LDRI), Universit\u00e9 Catholique de Louvain (UCLouvain)","place":["Brussels, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Mamede","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacognosy, Center of Interdisciplinary Research on Medicines (CIRM), University of Li\u00e8ge","place":["Li\u00e8ge, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romano","family":"Terrasi","sequence":"additional","affiliation":[{"name":"Bioanalysis and Pharmacology of Bioactive Lipids, Louvain Drug Research Institute (LDRI), Universit\u00e9 Catholique de Louvain (UCLouvain)","place":["Brussels, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-France","family":"H\u00e9rent","sequence":"additional","affiliation":[{"name":"Pharmacognosy Research Group, Louvain Drug Research Institute (LDRI), Universit\u00e9 Catholique de Louvain (UCLouvain)","place":["Brussels, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio G.","family":"Muccioli","sequence":"additional","affiliation":[{"name":"Bioanalysis and Pharmacology of Bioactive Lipids, Louvain Drug Research Institute (LDRI), Universit\u00e9 Catholique de Louvain (UCLouvain)","place":["Brussels, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Fr\u00e9d\u00e9rick","sequence":"additional","affiliation":[{"name":"Medicinal Chemistry Group, Louvain Drug Research Institute (LDRI), Universit\u00e9 Catholique de Louvain (UCLouvain)","place":["Brussels, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Frederich","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacognosy, Center of Interdisciplinary Research on Medicines (CIRM), University of Li\u00e8ge","place":["Li\u00e8ge, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Beloqui","sequence":"additional","affiliation":[{"name":"Department of Advanced Drug Delivery and Biomaterials, Louvain Drug Research Institute (LDRI), Universit\u00e9 Catholique de Louvain (UCLouvain)","place":["Brussels, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle","family":"Quetin-Leclercq","sequence":"additional","affiliation":[{"name":"Pharmacognosy Research Group, Louvain Drug Research Institute (LDRI), Universit\u00e9 Catholique de Louvain (UCLouvain)","place":["Brussels, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4493","DOI":"10.2147\/IJN.S167285","article-title":"Praziquantel\u2013lipid nanocapsules: an oral nanotherapeutic with potential Schistosoma mansoni tegumental targeting","volume":"13","author":"Amara","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"B2","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1186\/s12936-017-2054-y","article-title":"In vivo anti-malarial activity and toxicity studies of triterpenic esters isolated form Keetia leucantha and crude extracts","volume":"16","author":"Beaufay","year":"2017","journal-title":"Malar. J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/J.JDDST.2017.06.013","article-title":"Nanostructured lipid carriers as oral delivery systems for poorly soluble drugs","volume":"42","author":"Beloqui","year":"2017","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jep.2013.06.018","article-title":"In vivo antimalarial activity of Keetia leucantha twigs extracts and in vitro antiplasmodial effect of their constituents","volume":"149","author":"Bero","year":"2013","journal-title":"J. Ethnopharmacol."},{"key":"B5","unstructured":"CDC - malaria - about malaria - FAQs\n          \n          \n          2022"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e0141788","DOI":"10.1371\/JOURNAL.PONE.0141788","article-title":"Miltefosine lipid nanocapsules for single dose oral treatment of schistosomiasis mansoni: a preclinical study","volume":"10","author":"Eissa","year":"2015","journal-title":"PLoS One"},{"key":"B7","doi-asserted-by":"publisher","first-page":"10141","DOI":"10.3390\/molecules22030400","article-title":"Pentacyclic triterpene bioavailability: an overview of in vitro and in vivo studies","volume":"31","author":"Furtado","year":"2017","journal-title":"Molecules"},{"key":"B8","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1017\/S0031182020000645","article-title":"Human African trypanosomiasis: the current situation in endemic regions and the risks for non-endemic regions from imported cases","volume":"147","author":"Gao","year":"2020","journal-title":"Parasitology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1021\/ACS.MOLPHARMACEUT.4C01297","article-title":"Oral lipid-based nanomedicine for the inhibition of the cGAS-STING pathway in inflammatory bowel disease treatment","volume":"22","author":"Guilbaud","year":"2025","journal-title":"Mol. Pharm."},{"key":"B10","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1023\/A:1016121319668","article-title":"A novel phase inversion-based process for the preparation of lipid nanocarriers","volume":"196","author":"Heurtault","year":"2002","journal-title":"Pharm. Res."},{"key":"B11","article-title":"Human African trypanosomiasis (sleeping sickness)","author":"Hollingshead","year":"2024","journal-title":"StatPearls"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1038\/nprot.2007.303","article-title":"Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers","volume":"29","author":"Hubatsch","year":"2007","journal-title":"Nat. Protoc."},{"key":"B13","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jpba.2004.07.027","article-title":"Harmonization of strategies for the validation of quantitative analytical procedures: a SFSTP proposal - part I","volume":"36","author":"Hubert","year":"2004","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B14","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jpba.2007.06.032","article-title":"Harmonization of strategies for the validation of quantitative analytical procedures. A SFSTP proposal-Part III","volume":"45","author":"Hubert","year":"","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jpba.2007.06.013","article-title":"Harmonization of strategies for the validation of quantitative analytical procedures. A SFSTP proposal - part II","volume":"45","author":"Hubert","year":"","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B16","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.jpba.2008.07.018","article-title":"Harmonization of strategies for the validation of quantitative analytical procedures: a SFSTP proposal. Part IV. Examples of application","volume":"48","author":"Hubert","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/J.IJPHARM.2009.04.026","article-title":"Lipid nanocapsules: a new platform for nanomedicine","volume":"379","author":"Huynh","year":"2009","journal-title":"Int. J. Pharm."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1800222","DOI":"10.1002\/ARDP.201800222","article-title":"Ursolic acid: pharmacokinetics process in vitro and in vivo, a mini review","volume":"352","author":"Jinhua","year":"2019","journal-title":"Arch. Pharm. Weinh."},{"key":"B19","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3390\/PHARMACEUTICS13050595\/S1","article-title":"New in vitro coculture model for evaluating intestinal absorption of different lipid nanocapsules","volume":"13","author":"Kaeokhamloed","year":"2021","journal-title":"Pharmaceutics"},{"key":"B20","doi-asserted-by":"publisher","first-page":"795","DOI":"10.51583\/IJLTEMAS.2025.140400094","article-title":"The potential of ursolic acid nanoformulations as drug delivery systems in alzheimer\u2019s disease therapy and research","volume":"14","author":"Kaushik","year":"2025","journal-title":"Int. J. Latest Technol. Eng. Manag. Appl. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/J.IJPHARM.2004.03.018","article-title":"Lipid nanocarriers as drug delivery system for ibuprofen in pain treatment","volume":"278","author":"Lamprecht","year":"2004","journal-title":"Int. J. Pharm."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.foodchem.2011.09.125","article-title":"Quantification of rotenone in seeds of different species of yam bean (Pachyrhizus sp.) by a SPE HPLC-UV method","volume":"131","author":"Lauti\u00e9","year":"2012","journal-title":"Food Chem."},{"key":"B23","unstructured":"2024"},{"key":"B24","doi-asserted-by":"publisher","first-page":"100595","DOI":"10.1016\/J.IJPDDR.2025.100595","article-title":"Metabolomics study of 3-O-p-(Z\/E)-coumaroyltormentic acid-treated Trypanosoma brucei brucei","volume":"28","author":"Mamede","year":"2025","journal-title":"Int. J. Parasitol. Drugs Drug Resist"},{"key":"B25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/S12936-025-05762-3","article-title":"Natural triterpenic phenolic esters target PfA-M17 in Plasmodium falciparum","volume":"251","author":"Mamede","year":"2026","journal-title":"Malar. J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/J.IJPHARM.2016.02.019","article-title":"Lipid-based nanoformulations for peptide delivery","volume":"502","author":"Matougui","year":"2016","journal-title":"Int. J. Pharm."},{"key":"B27","unstructured":"Rev 1* EU individual case safety report (ICSR) 1 implementation guide start of public consultation of first version individual case safety reports (ICSRs) in pharmacovigilance-part 2: human pharmaceutical reporting requirements for ICSR (ISO 27953-2:2011) and the ICH E2B(R3) implementation guide\n          \n          \n            \n              Medicines Agency\n              E.\n            \n          \n          \n          2017"},{"key":"B28","volume-title":"An oral malaria therapy: curcumin-loaded lipid-based drug delivery systems combined with \u03b2-arteether","author":"Memvanga","year":"2013"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/J.JEP.2011.07.037","article-title":"Permeability of Rosmarinic acid in Prunella vulgaris and ursolic acid in Salvia officinalis extracts across Caco-2 cell monolayers","volume":"137","author":"Qiang","year":"2011","journal-title":"J. Ethnopharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1080\/21691401.2019.1573739","article-title":"Ursolic acid nanoparticles for oral delivery prepared by emulsion solvent evaporation method: characterization, in vitro evaluation of radical scavenging activity and bioavailability","volume":"47","author":"Qiu","year":"2019","journal-title":"Artif. Cells, Nanomedicine, Biotechnol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1016\/j.jchromb.2009.03.018","article-title":"An improved HPLC-UV method for the simultaneous quantification of triterpenic glycosides and aglycones in leaves of Centella asiatica (L.) Urb (APIACEAE)","volume":"877","author":"Rafamantanana","year":"2009","journal-title":"J. Chromatogr. B"},{"key":"B32","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.jpba.2010.12.018","article-title":"Advances in validation, risk and uncertainty assessment of bioanalytical methods","volume":"55","author":"Rozet","year":"2011","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B33","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3390\/PH15080975","article-title":"Intestinal absorption study: challenges and absorption enhancement strategies in improving oral drug delivery","volume":"15","author":"Sabri","year":"2022","journal-title":"Pharmaceuticals"},{"key":"B34","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/OPEN.202100159","article-title":"Design, synthesis and biological activity of C3 hemisynthetic triterpenic esters as novel antitrypanosomal hits","volume":"10","author":"Schioppa","year":"","journal-title":"ChemistryOpen"},{"key":"B35","doi-asserted-by":"publisher","first-page":"7154","DOI":"10.3390\/MOLECULES26237154","article-title":"A validated HPLC-PDA-HRMS method to investigate the biological stability and metabolism of antiparasitic triterpenic esters","volume":"26","author":"Schioppa","year":"","journal-title":"Molecules"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/J.1749-6632.2009.04925.X","article-title":"Tight junctions: molecular structure meets function","volume":"1165","author":"Schulzke","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"8235","DOI":"10.3390\/IJMS15058235","article-title":"Betulinic acid in complex with a gamma-cyclodextrin derivative decreases proliferation and in vivo tumor development of non-metastatic and metastatic B164A5 cells","volume":"15","author":"Soica","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/2211068214561025","article-title":"TEER measurement techniques for in vitro barrier model systems","volume":"20","author":"Srinivasan","year":"2015","journal-title":"J. Lab. Autom."},{"key":"B39","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/J.IJPHARM.2015.11.042","article-title":"Synergistic interactions between doxycycline and terpenic components of essential oils encapsulated within lipid nanocapsules against gram negative bacteria","volume":"498","author":"Valcourt","year":"2016","journal-title":"Int. J. Pharm."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.2217\/nnm-2016-0251","article-title":"Potential use of nanocarriers with pentacyclic triterpenes in cancer treatments","volume":"12","author":"Vald\u00e9s","year":"2016","journal-title":"Nanomedicine"},{"key":"B41","unstructured":"2025"},{"key":"B42","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/J.JCHROMB.2010.11.037","article-title":"Quantitation of ursolic acid in human plasma by ultra performance liquid chromatography tandem mass spectrometry and its pharmacokinetic study","volume":"879","author":"Xia","year":"2011","journal-title":"J. Chromatogr. B"},{"key":"B43","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1021\/acs.molpharmaceut.7b00742","article-title":"Size effect on lipid nanocapsule-mediated GLP-1 secretion from enteroendocrine L cells","volume":"15","author":"Xu","year":"2018","journal-title":"Mol. Pharm."}],"container-title":["Frontiers in Drug Delivery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fddev.2026.1846904\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:01:47Z","timestamp":1780466507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fddev.2026.1846904\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":43,"alternative-id":["10.3389\/fddev.2026.1846904"],"URL":"https:\/\/doi.org\/10.3389\/fddev.2026.1846904","relation":{},"ISSN":["2674-0850"],"issn-type":[{"value":"2674-0850","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"article-number":"1846904"}}